View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps
PER Pulse™ Recaps for the Renal Cell Carcinoma: State-of-the-Art Sequencing in an Era of Increasing Treatment Options symposium focus on current treatment algorithms, new agents, and management of adverse events in patients with renal cell carcinoma that were discussed by the expert faculty at this program.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Exelixis, Pfizer, and Prometheus Laboratories Inc.

Community Practice Connections: Renal Cell Carcinoma: State-of-the-Art Sequencing in an Era of Increasing Treatment Options

Release Date: September 12, 2016
Expiration Date: September 12, 2017
Media: Internet - based

Activity Overview

This activity focuses on optimized therapeutic sequencing for patients with advanced renal cell carcinoma (RCC). It features a series of short video interviews with leading experts in the field. The content and interviews are based on presentations given in June 2016 at Renal Cell Carcinoma: State-of-the-Art Sequencing in an Era of Increasing Treatment Options, a CME-certified, ancillary satellite symposium of a major oncology annual meeting in Chicago, IL.
Program Chair Toni Choueiri, MD, and the faculty, Bernard Escudier, MD, Robert Figlin, MD, David McDermott, MD, and Thomas Hutson, DO, PharmD, engage in case-based discussions of clinical strategies for metastatic RCC management, and offer their perspectives on the latest clinical evidence and practice recommendations, including adverse-event management. Throughout the activity, interactive online questions are posed to participants to assess knowledge and facilitate self-assessment.
Key topics discussed in this activity include:

  • Biology of RCC, including molecular targets and the mechanistic rationale for therapeutic drug development in the field
  • Role and application of VEGF-targeted therapies in frontline and subsequent lines of care
  • Sequencing of strategies in the context of current and emerging therapeutic approaches
  • Practical management recommendations on both predictable and rare treatment-related toxicities for patients who receive immunotherapeutic and targeted strategies
  • The clinical relevance of new data


Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is intended for actively practicing medical oncologists, surgical oncologists, nurse practitioners, advanced practice nurses, oncology nurses, and other physicians who are involved in the care of patients with RCC.

Educational Objectives

At the conclusion of this activity, participants should be better prepared to:
  • Assess standard approaches for the management of advanced RCC and unanswered questions in the field regarding sequencing of therapies 
  • Describe the mechanistic rationale for applying novel targeted and immunotherapeutic strategies in the setting of RCC 
  • Apply knowledge concerning adverse event profiles to consider their impact on clinical decision making to individualize sequencing and manage predictable treatment-related toxicities related to treatments for RCC 
  • Incorporate an evidence-based approach to determine optimal sequencing

Faculty, and Staff Disclosures

Toni Choueiri, MD
Clinical Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosure: Research Support: Pfizer, Novartis, Exelixis, Bristol-Myers Squibb, Merck, Tracon Pharmaceuticals, AstraZeneca; Consultant: Pfizer, Merck, GlaxoSmithKline, Roche, Eisai, Prometheus Labs Inc, Novartis.

Bernard Escudier, MD
Chair, Genitourinary Oncology Committee
Gustave Roussy Institute
Paris, France

Disclosure: Consultant: Pfizer, Novartis, Bristol-Myers Squibb, Exelixis, Roche.


Robert Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology-Oncology
Professor of Biomedical Sciences
Professor of Medicine
Director, Division of Hematology/Oncology
Cedars-Sinai Medical Center
Associate Director, Academic Program Development in the Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA

Disclosure: Grant/Research Support: GlaxoSmithKline, Bristol-Myers Squibb, Immatics, Argos Therapeutics, Exelixis, Cerulean Pharma Inc, Peloton Therapeutics Inc; Consultant: Novartis, Pfizer.

Thomas Hutson, DO, PharmD, FACP
Director, GU Oncology Program
Co-Director, GU Center of Excellence
Texas Oncology
Charles A. Sammons Cancer Center
Baylor University Medical Center
Professor of Medicine, Texas A&M HSC College of Medicine
Co-Chair, GU Research, US Oncology and McKesson
Dallas, TX

Disclosure: Grant/Research Support: Pfizer, Bristol-Myers Squibb, Exelixis, Eisai, AVEO Pharmaceuticals Inc; Consultant: Pfizer, Bristol Myers Squibb, Exelixis, Eisai, AVEO Pharmaceuticals Inc; Speaker’s Bureau: Pfizer, Bristol-Myers Squibb, Exelixis, Janssen Pharmaceuticals Inc, Astellas.

David McDermott, MD
Associate Professor, Medicine
Harvard Medical School
Staff Physician, Hematology/Oncology
Beth Israel Deaconess Medical Center
Director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology
Beth Israel Deaconess Medical Center
Boston, MA

Disclosure: Grant/Research Support: Kidney Cancer Research, Prometheus; Consultant: Kidney Cancer Research, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharma, Genentech, BioOncology.

The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests.

Disclosure Policy and Resolution of Conflicts of Interest 

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

CME Provider Contact Information 
Physicians’ Education Resource, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705

Calendar of Events
Filter By